Non-invasive in vivo imaging of tumour-associated cathepsin B by a highly selective inhibitory DARPin by Kramer, Lovro et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2017
Non-invasive in vivo imaging of tumour-associated cathepsin B by a highly
selective inhibitory DARPin
Kramer, Lovro; Renko, Miha; Završnik, Janja; Turk, Dušan; Seeger, Markus A; Vasiljeva, Olga;
Grütter, Markus G; Turk, Vito; Turk, Boris
Abstract: Cysteine cathepsins often contribute to cancer progression due to their overexpression in the
tumour microenvironment and therefore present attractive targets for non-invasive diagnostic imaging.
However, the development of highly selective and versatile small molecule probes for cathepsins has been
challenging. Here, we targeted tumour-associated cathepsin B using designed ankyrin repeat proteins
(DARPins). The selective DARPin 8h6 inhibited cathepsin B with picomolar affinity (Ki = 35 pM) by
binding to a site with low structural conservation in cathepsins, as revealed by the X-ray structure of the
complex. DARPin 8h6 blocked cathepsin B activity in tumours ex vivo and was successfully applied in
in vivo optical imaging in two mouse breast cancer models, in which cathepsin B was bound to the cell
membrane or secreted to the extracellular milieu by tumour and stromal cells. Our approach validates
cathepsin B as a promising diagnostic and theranostic target in cancer and other inflammation-associated
diseases.
DOI: https://doi.org/10.7150/thno.19081
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-139762
Published Version
 
 
Originally published at:
Kramer, Lovro; Renko, Miha; Završnik, Janja; Turk, Dušan; Seeger, Markus A; Vasiljeva, Olga; Grütter,
Markus G; Turk, Vito; Turk, Boris (2017). Non-invasive in vivo imaging of tumour-associated cathepsin
B by a highly selective inhibitory DARPin. Theranostics, 7(11):2806-2821.
DOI: https://doi.org/10.7150/thno.19081
Theranostics 2017, Vol. 7, Issue 11 
 
 
http://www.thno.org 
2806 
Theranostics 
2017; 7(11): 2806-2821. doi: 10.7150/thno.19081 
Research Paper 
Non-invasive in vivo imaging of tumour-associated 
cathepsin B by a highly selective inhibitory DARPin 
Lovro Kramer1, 2, Miha Renko1, Janja Završnik1, 2, Dušan Turk1, 3, Markus A. Seeger4, Olga Vasiljeva1, 
Markus G. Grütter5, Vito Turk1, Boris Turk1, 3 
1. Jozef Stefan Institute, Department of Biochemistry and Molecular and Structural Biology, Ljubljana, Slovenia; 
2. International Postgraduate School Jozef Stefan, Ljubljana, Slovenia; 
3. Center of Excellence CIPKEBIP, Ljubljana, Slovenia; 
4. Institute of Medical Microbiology, University of Zürich, Zürich, Switzerland; 
5. Department of Biochemistry, University of Zürich, Zürich, Switzerland. 
 Corresponding author: boris.turk@ijs.si 
© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license 
(https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. 
Received: 2017.01.06; Accepted: 2017.04.15; Published: 2017.07.08 
Abstract 
Cysteine cathepsins often contribute to cancer progression due to their overexpression in the tumour 
microenvironment and therefore present attractive targets for non-invasive diagnostic imaging. 
However, the development of highly selective and versatile small molecule probes for cathepsins has 
been challenging. Here, we targeted tumour-associated cathepsin B using designed ankyrin repeat 
proteins (DARPins). The selective DARPin 8h6 inhibited cathepsin B with picomolar affinity (Ki = 35 
pM) by binding to a site with low structural conservation in cathepsins, as revealed by the X-ray 
structure of the complex. DARPin 8h6 blocked cathepsin B activity in tumours ex vivo and was 
successfully applied in in vivo optical imaging in two mouse breast cancer models, in which cathepsin B 
was bound to the cell membrane or secreted to the extracellular milieu by tumour and stromal cells. 
Our approach validates cathepsin B as a promising diagnostic and theranostic target in cancer and other 
inflammation-associated diseases. 
Key words: protease, cathepsin B, designed ankyrin repeat protein (DARPin), non-invasive diagnostic imaging, 
tumour microenvironment. 
Introduction 
Non-invasive whole-body monitoring of 
tumour-associated proteins is essential for developing 
a proper understanding of the involvement of 
proteins in disease and can lead to the development of 
new diagnostic and therapeutic approaches [1, 2]. 
Among these proteins, tumour-associated proteases 
have gained attention in non-invasive imaging and as 
drug targets due to their high up-regulation and 
accumulation within the tumour microenvironment. 
Their excessive proteolysis critically contributes to 
tumorigenesis by affecting tumour cell invasiveness, 
angiogenesis, immune cell infiltration and metastasis 
[3-5]. In the last decade, cysteine cathepsins in 
particular have been recognized as major players in 
cancer biology [5]. Although there are 11 human 
cathepsins known at the gene level, they do not all 
contribute equally to cancer. Based on animal and 
clinical studies, the major contributors are cathepsins 
(Cat) B, S, K, L and X. CatB and CatS have been found 
to be heavily up-regulated in cancer [6, 7], where they 
are primarily secreted into the tumour 
microenvironment by immune cells [8-11], including 
tumour-associated macrophages. Moreover, CatB was 
found to be one of the most abundantly secreted 
proteins in the macrophage secretome [12]. This 
tumour-specific translocation to the cell membrane 
and tumour interstitium [13] makes CatB particularly 
interesting as a tumour-associated antigen in contrast 
to classical targets such as cell membrane receptors or 
cell-adhesion molecules [14].  
Therefore, it is not surprising that members of 
the cathepsin family of proteases were among the first 
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enzymes targeted in vivo by activatable fluorescent 
reagents [15]. Activity-based approaches have been 
the method-of-choice and have led to the 
development of several NIR fluorescent substrates 
[16, 17] and activity-based probes (ABPs) [18-20]. 
These tools are particularly useful since they provide 
low-background signals until they are processed, 
although substrate-based probes have the downside 
of diffusing from the target enzyme after cleavage, 
resulting in rapid clearance of the signal from the 
target location. This has, in part, been overcome by 
adding a homing component such as a lipid moiety to 
the substrate [21]. On the other hand, ABPs have the 
unique characteristic of irreversible covalent 
association with the target enzyme after their 
activation (ABPs are suicide inhibitors). This is of 
particular use in pre-clinical research, as it allows 
proteomic-based identification and quantification of 
targets [22, 23], but does not enable any signal 
amplification, which is problematic with 
low-abundance enzymes. A major limitation of 
optical diagnostic imaging in humans based on 
fluorescence is the relatively poor tissue penetration 
of NIR light, which led to modifications of ABPs with 
PET tracers. In this manner, the issue of tissue 
penetration for imaging has been solved, but the 
quenching principle has been lost [24, 25]. 
Central to all activity-based tools is targeting the 
enzyme active site, which is highly conserved in 
cathepsins and makes the development of truly 
selective tools challenging. Discrimination among 
different family members is difficult to achieve due to 
the exclusive focus on the active site while completely 
disregarding the structural variability of other 
regions. Furthermore, even minor modifications to 
small-molecule probes can severely affect their 
selectivity and bioavailability [26-28]. We therefore 
explored the possibility of targeting CatB by designed 
ankyrin repeat proteins (DARPins). In this approach, 
there is no inherent bias to target the structurally 
conserved active site region of a protease, as the 
targeting ligand from the DARPin library is obtained 
solely on the basis of strong and selective 
protein-protein interactions [29, 30]. These small and 
rigid antibody mimetics are obtained completely in 
vitro by ribosome or phage display and can be 
expressed as recombinant proteins in E. coli with high 
yields. Each of the repeat motives in DARPins is 
composed of 33 amino acid residues folded into a 
β-turn, followed by two antiparallel α-helices and a 
loop connecting to the next repeat, which yields a 
highly stable structure. The selectivity for their 
respective targets comes from the 7-10 randomized 
amino acids in each of the internal repeats. Moreover, 
DARPins offer the possibility of multiple site-specific 
modifications for pharmacokinetic fine-tuning and 
imaging label conjugation (i.e., NIR fluorescent dye, 
PET/SPECT tracer) without the loss of selectivity and 
affinity [31, 32]. They also have certain advantages in 
imaging over conventional antibodies, including 
higher tissue penetration and fast blood clearance 
following systemic administration [33].  
Here, we present the development of DARPin 
8h6, which binds to CatB with picomolar affinity at a 
site of high structural variability in the family of 
cysteine cathepsins. This resulted in complete 
selectivity over other important cancer-related 
cathepsins (S, K, L and X), confirming the rationale for 
selective targeting via binding to a variable surface 
separate from the protease active site Cys residue. The 
extremely high affinity between DARPin 8h6 and 
CatB proved to be critical for successful localization of 
CatB in vivo in tumours of two mouse breast cancer 
models, in which CatB was confirmed to be an 
excellent target with the potential to be used as a 
diagnostic marker. 
Materials and methods 
DARPin selection and production 
DARPins 8h6 and 81 were selected by ribosome 
display from the recently developed DARPin 2.0 
library [34] as described in the supplementary 
material, expressed from the pQE30 vector in E. coli 
XL-1 Blue cells and purified by Ni2+ affinity and 
size-exclusion chromatography. When C-terminally 
labelled DARPins were used, a C-terminal Cys, which 
is the only Cys in the DARPin sequence, was 
introduced by mutagenesis. Biotin or cyanine5.5 
(Cy5.5) tags were covalently attached via the 
maleimide linker, and the labelling efficiency was 
confirmed as described in the supplementary 
material. 
Solid-phase affinity assay 
Cathepsins (200 nM) were immobilized to a 
96-well MaxiSorp plate (Nunc) in PBS (20 mM sodium 
phosphate, 150 mM NaCl, pH 7.0) by incubation 
overnight at 4 °C. After blocking with 3 % BSA in TBS 
(50 mM Tris/HCl, 500 mM NaCl, pH 7.0) with 0.05 % 
Tween-20 (TBST), C-terminally biotinylated DARPins 
were incubated for 1 h at 4 °C in TBST, followed by 
three washes with TBST and subsequent incubation 
with streptavidin-HRP (1:10000, Thermo Fisher) for 30 
min. Following four washes with TBST, 1 mg mL-1 
2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid 
(ABTS) and 0.06 % H2O2 were added in 0.1 M citric 
acid-Na2HPO4, pH 4.5, for 30 min, after which the 
absorbance at 405 nm was measured using a Tecan 
Infinite M1000 plate reader (Tecan, Austria). 
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Inhibition of cathepsin activity 
Recombinant cathepsins (human CatB 1 nM, 
mouse CatB 1 nM, human CatL 1 nM, human CatK 1 
nM, human CatS 10 nM, mouse CatS 10 nM, human 
CatX 250 nM) were incubated for 15 min at 37 °C with 
10 µM DARPins in 0.1 M phosphate buffer, pH 6.0, 
containing 5 mM DTT, 1 mM EDTA, 0.1 % PEG6000 
and 0.1 % BSA. Enzymatic activity was determined by 
the addition of 20 µM substrate (z-Arg-Arg-AMC for 
CatB, z-Phe-Arg-AMC for other cathepsins) and 
measuring the linear slopes (initial rates) of the 
fluorescence of the liberated product (em/ex = 
370/460 nm) over time using the Tecan Infinite M1000 
plate reader. Residual activity was defined as the 
fraction (%) of activity in the absence of DARPin.  
The kinetics of the inhibition of CatB by 
DARPins was performed essentially as described 
previously [35]. Briefly, the inhibition type was 
determined according to the general modifier scheme 
(Fig. S4a) [36] with 1 nM CatB by varying the 
concentrations of DARPin 8h6 (25-400 nM) and the 
substrate z-Arg-Arg-AMC (75-600 µM, KM (human 
CatB) = 173 µM, KM (mouse CatB) = 262 µM) in 0.1 M 
phosphate buffer, pH = 6.0, containing 5 mM DTT, 1 
mM EDTA and 0.1 % PEG6000. Graphical analysis 
with Prism5 (GraphPad Software) was used to 
determine the parameter α, which corresponds to the 
ratio between competitive and uncompetitive Ki, and 
β, which represents incomplete inhibition at 
saturating inhibitor concentrations (i.e., hyperbolic 
inhibition). To determine the Ki values, the initial 
velocities at fixed CatB (50 pM) and z-Arg-Arg-AMC 
(30 µM) concentrations were measured in the 
presence of increasing DARPin concentrations (50 pM 
- 5 nM). The velocities were fitted considering the 
tight-binding, hyperbolic, mixed-mode inhibition as 
described previously [37]. 
Structure determination 
Complexes between human CatB and DARPin 
8h6 or human CatB and DARPin 81 were formed by 
mixing the proteins CatB:DARPin in a ratio of 1:2 
(M/M) in 20 mM sodium phosphate, 300 mM NaCl, 
pH 7.0, and isolated using a Superdex S200 
size-exclusion column, followed by concentrating via 
Amicon Ultra-15 Centrifugal Filter Units with a 10 
kDa cut-off (EMD Millipore) to approximately 10 mg 
mL-1. Crystals were grown using the sitting drop 
method in 0.1 M sodium citrate, pH = 4.0 with 15 % 
PEG6000 (DARPin 8h6 complex) or in 0.1 M MES, 1.8 
M AmSO4 (DARPin 81 complex). The crystals were 
soaked in mother liquor supplemented with 25 % 
glycerol and frozen in liquid N2 prior to data 
collection. Diffraction data were collected on MX14.1 
at Synchrotron Desy (Berlin, Germany) and processed 
using XDSAPP/XDS. Molecular replacement was 
performed using the crystal structures of CatB (PDB 
ID 3AI8) and DARPin E3_5 (PDB ID 4J7W). 
Refinement was performed using REFMAC [38] and 
MAIN [39]. Model building was performed using 
MAIN. Structural figures were prepared using 
PyMOL (www.pymol.org). 
Cell cultures  
Primary PyMT cells were prepared from 
tumours of 14-week-old FVB/N-TgN(MMTVPyMT) 
mice as described previously [40], whereas 4T1 cells 
were obtained from ATCC (ATCC CRL-2539). Both 
types of cells were grown in DMEM medium 
containing 10 % FBS, 1 % PS and 1 % Glutamax; 
differentiated bone-marrow derived macrophages 
(dBMMs) were prepared from FVB/N mice as 
described previously [41]. Briefly, the isolated bone 
marrow progenitors were differentiated into 
macrophages in the presence of M-CSF by 7 day 
incubation with DMEM containing 20 % 
heat-inactivated FBS, 1 % PS, 1 % Glutamax and 15 % 
L929 conditioned medium. U87-MG (ECACC 
89081402) and HeLa cells (ECACC 93021013) were 
obtained from ECACC and grown in MEM medium 
containing 10 % FBS, 1 % PS, 1 % non-essential amino 
acids and 1 % Glutamax.  
Detection of cell membrane-associated CatB 
Cells (40,000 per well) were seeded onto black 
96-well plates with transparent bottoms and grown 
overnight. Active endocytosis was initially blocked by 
a 1 h incubation at 4 °C; to prevent any additional 
endocytosis, all subsequent steps were also performed 
at 4 °C. Goat anti-mouse CatB polyclonal antibodies 
(1:1000, AF965, R&D), mouse anti-human CatB 
monoclonal antibodies 3E1 (100 nM, [6]) or 
biotinylated DARPins (100 nM) were next added in 
PBS supplemented with 3 % BSA and incubated for 1 
hour. After washing with PBS, the 
Alexa488-conjugated secondary anti-goat antibodies 
(1:1000, Thermo Fisher Scientific), anti-mouse 
antibodies (1:1000, Thermo Fisher Scientific) or 
Alexa488-conjugated streptavidin (1:1000, Thermo 
Fisher Scientific) was added for 1 hour. After 
washing, the cell membrane-associated fluorescence 
(ex/em = 488/520 nm) was monitored in a Tecan 
Infinite M-1000 plate reader by measuring nine 
locations in each well. The mean background 
fluorescence (where only secondary antibody or only 
streptavidin was incubated) was subtracted from the 
measurements. In the control experiments in which 
unlabelled competitor DARPins were used to block 
cell membrane-associated CatB binding to 
biotinylated DARPin 8h6, the competitor DARPins (1 
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µM) were incubated with cells during the last 30 min 
of active endocytosis blocking. 
Measurement of cell membrane-associated 
CatB activity 
The measurement was performed as described 
previously [42]. Briefly, 10,000 cells were seeded onto 
black 96-well plates with transparent bottoms and 
grown overnight. Cells were then incubated with 
Hank’s balanced salt solution lacking sodium 
bicarbonate and containing 0.6 mM CaCl2, 0.6 mM 
MgCl2, 2 mM L-cysteine, 25 mM PIPES, pH 7.0 for 30 
min at 37 °C. The solution was then replaced with 
fresh buffer containing 50 µM z-Arg-Arg-AMC in the 
absence or presence of DARPin (100 nM) and 
fluorescence (em/ex = 370/460 nm) was monitored 
over time using the Tecan Infinite M-1000 plate 
reader. Data analysis was performed using Prism5 
(GraphPad Software). 
Three-dimensional cell invasion assay 
Multicellular tumour spheroids (MCTS) were 
prepared as described previously [43]. MCTSs were 
then transferred to a U-bottom 96-well plate coated 
with 25 µL Matrigel (5 mg/mL) in serum-free DMEM 
and additionally covered with 25 µL Matrigel (5 
mg/mL) in serum-free DMEM. After 1 h, 100 µL of 
complete medium was added and the spheroid size 
was imaged 24 h later using Olympus IX 81 inverted 
microscope (Olympus). The volume of the spheroids 
was calculated as V = π/6 × (spheroid length) × 
(spheroid width)2. Where noted, inhibitors were 
added at the designated concentrations to both the 
Matrigel and the culture medium. 
In situ binding to native tumour tissues 
Cryopreserved PyMT tumour tissues were cut 
into 5 µm thick slices and thawed at 4 °C. To prevent 
tissue damage, all subsequent steps were also 
performed at 4 °C. In the next step, slices were 
incubated with PBS containing 3 % BSA for 15 min, 
followed by a 30 min incubation with C-terminally 
biotinylated DARPins (1 µM). After three washing 
steps with PBS, Alexa488-conjugated streptavidin 
(1:1000) was added for 30 min. After additional 
washing with PBS, slices were mounted with Prolong 
Gold antifade reagent containing DAPI and imaged 
on IX81 microscope (Olympus) with Imaging 
Software for Life Science Microscopy Cell. 
In situ zymography 
Cryopreserved PyMT tumour tissues were cut 
into 5-µm thick slices and thawed at room tempera-
ture. The slices were incubated for 1 hour in 20 mM 
sodium phosphate, 137 mM NaCl, pH 7.0 with 2.7 
mM L-cysteine, 0.25 mM EDTA, 1 mM DTT, 1 mM 
5-nitrosalicylaldehyde and 1 mg mL-1 z-Arg-Arg- 
4MβNA. DARPins E3_5 (1 µM), 8h6 (1 µM) or CA074 
(1 µM) were added where indicated. After 1 h, the 
slices were mounted with Prolong Gold antifade 
reagent containing DAPI and microscopy was per-
formed as described above. In the procedure 5-nitro-
salicylaldehyde forms a Schiff base with proteo-
lytically released 4-methoxy-β-naphthylamine to ge-
nerate a yellow fluorescent final reaction product [44]. 
In vivo and ex vivo imaging 
Mice were used in accordance with the protocols 
approved by the Veterinary Administration of the 
Republic of Slovenia (VARS) and the government 
Ethical Committee. Procedures for animal care and 
use were in accordance with the “PHS Policy on 
Human Care and Use of Laboratory Animals” and the 
“Guide for the Care and Use of Laboratory Animals” 
(NIH publication 86-23, 1996).  
In the tumour imaging study we used a congenic 
PyMT model [45] and a syngeneic 4T1 model [21]. 
Briefly, PyMT and 4T1 cells were grown to 
subconfluency as described above, detached by 
trypsinization and resuspended in DMEM at a 
concentration of 5×106 cells mL-1 and 1×106 cells mL-1, 
respectively. One hundred microliters of the cell 
suspension was then injected into the left inguinal 
mammary gland of the recipient mouse (congenic 
FVB/N mice for PyMT cells; Balb/c strain for 4T1 
cells) and tumours were allowed to grow for 2-3 
weeks until they reached 100-150 mm3. 
Mice (n=3) received 1 nmol (approx. 20 µg) of 
C-terminally Cy5.5 labelled DARPins in 100 µL of PBS 
by intravenous (i.v.) administration. At designated 
time-points (30 min, 3 h, 6 h, 24 h, 48 h, 72 h), mice 
were anesthetized with 2 % isofluorane and 
transferred to the IVIS Spectrum small animal 
imaging system (Perkin Elmer), where isofluorane 
anaesthesia was maintained for the duration of 
imaging. Imaging was performed using the ex/em = 
675/720 nm bandpass filters. Image analysis was 
performed in Living Image Software 4.3.1 (Perkin 
Elmer), where false blue-hot images of radiant 
efficiency (radiance (photons per second per square 
centimetre per steradian) per incident excitation 
power (microwatt per square cm)) were overlaid on 
bright-light images. For quantification of radiant 
efficiency, equally sized round regions of interest 
(ROI) were selected at the site of the tumour and 
contralateral mammary gland. In case of pretreatment 
with unlabelled DARPin 8h6, 10 nmol of the 
unlabelled DARPin in 100 µL of PBS were 
administered i.v. 1 h prior to Cy5.5-labelled DARPin 
administration. 
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Figure 1. DARPin 8h6 selectivity and affinity. (a) Colorimetric affinity assay with immobilized recombinant cathepsins (50 nM). Increasing concentrations of 
C-terminally biotinylated DARPin 8h6 were incubated in 96-well plates with immobilized recombinant cathepsins. After washing, the biotin tag was detected by 
streptavidin-HRP. (b) Residual proteolytic activity (% of uninhibited) of recombinant cathepsins (human CatB 1 nM, mouse CatB 1 nM, human CatL 1 nM, human CatK 
1 nM, human CatS 10 nM, mouse CatS 10 nM, human CatX 250 nM) in the presence of 10 µM DARPin 8h6; z-Arg-Arg-AMC was used for measuring CatB activity and 
z-Phe-Arg-AMC for other cathepsins. The experiment was performed in triplicate and is presented as the mean ± standard error. (c) Inhibition of human CatB (50 
pM) and mouse CatB (50 pM) by DARPin 8h6 (50 pM – 5 nM). The solid line represents the least-squared fit for the hyperbolic tight-binding inhibition, as described 
in Materials and methods. The proteolytic activity was measured by z-Arg-Arg-AMC (30 µM). 
 
For ex vivo analysis of organ biodistribution, 
mice (n = 4) were sacrificed at 3 h or 72 h time-points 
post DARPin administration. Organs (tumour, liver, 
lungs, heart, kidneys, spleen and intra-abdominal 
lymph nodes) were collected and immediately 
imaged by IVIS Spectrum as described above.  
Immunohistochemistry 
Cryopreserved PyMT tumours from mice with 
administered Cy5.5 labelled DARPin 8h6 were cut 
into 5-µm sections and air-dried for 20 min, followed 
by fixation in ice-cold methanol for 5 min and acetone 
(-20 °C) for 2 min. Slices were rehydrated in PBS for 15 
min and labelled with anti-F4/80 antibody (1:200, 
ab6640, Abcam) and Alexa488-labelled anti-rat 
secondary antibody (Thermo Fisher Scientific). Slices 
were mounted with Prolong Gold antifade reagent 
containing DAPI and microscopy was performed as 
described above. 
Streptavidin pull-down 
Fourteen-week-old FVB/N-TgN (MMTVPyMT) 
mice with developed tumours were used in the 
experiment. Mice were anesthetised with 2 % 
isofluorane and C-terminally biotinylated DARPins (5 
nmol) were intratumourally injected into one tumour 
per mouse. After thirty minutes, mice were sacrificed, 
tumours were collected and tumour extracts were 
obtained by tissue (50 µg) disruption using 
Ultrathurrax (IKA, Staufen, Germany) in 200 µL of 
tissue lysis buffer (0.25 M Tris-HCl, pH 7.0, 5 mM 
EDTA, 1 % Triton X-100). The extracts were incubated 
with 10 µL of Pierce™ Streptavidin Agarose (Thermo 
Fisher Scientific) for 30 min on 4 °C. After three 
washes with PBS, the beads were resuspended in 
SDS-PAGE loading buffer and boiled for 5 min, 
followed by SDS-PAGE and immunoblotting using 
anti-CatB antibodies or streptavidin-HRP. 
Statistical analysis 
Statistical analysis was performed by a 
two-tailed t-test for two groups and one-way analysis 
of variance with Turkey’s post-hoc test for multiple 
groups using Prism 5 (GraphPad Software). A p value 
< 0.05 was considered statistically significant. 
Results 
DARPin 8h6 and CatB interact with high 
selectivity and affinity 
DARPin 8h6 was selected using ELISA screening 
after eight successive rounds of ribosome display 
against both human and mouse recombinant CatB 
from a recently described DARPin library [34]. In 
order to achieve site-specific chemical labelling with 
biotin or Cy5.5, a unique cysteine residue was 
introduced at the C-terminus that allowed 
conjugation with maleimide linkers (Figs. S1-S3). The 
selectivity of DARPin 8h6 binding to CatB was 
determined in a solid-phase affinity assay in which 
only human and mouse CatB bound to biotinylated 
DARPin 8h6 in a concentration-dependent manner. 
There was no signal for cathepsins L, K, S or X with up 
to 1 µM of DARPin (Fig. 1a).  
Next, we found that DARPin 8h6 almost 
completely inhibited both human and mouse CatB 
activities, whereas other cathepsins were not inhibited 
(Fig. 1b). A detailed kinetic analysis of the DARPin 
8h6-CatB interaction revealed fast, tight-binding 
characteristics, with inhibition constants of 34 pM and 
35 pM for human and mouse CatB, respectively (Fig. 
1c, Fig. S4b-e). In both cases, the mechanism was 
mixed-mode inhibition with a very strong 
competitive component, as represented by the 
parameter α>1 (Fig. S4a). This indicated that DARPin 
8h6 competes for binding with the z-Arg-Arg-AMC 
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substrate, although the ternary enzyme-inhibitor- 
substrate complex can still form (i.e., uncompetitve 
inhibition, where α⋅Ki is the uncompetitive inhibition 
constant), but with roughly six-fold lower affinity (Ki 
= 34 pM, α⋅Ki = 224 pM for human CatB; Ki = 35 pM, 
α⋅Ki = 214 pM for mouse CatB). Furthermore, the 
ternary complex was partially productive for the 
substrate (β > 0), although with substantially lower 
efficiency, suggesting that DARPin 8h6 does not 
directly bind to the active site of CatB. As subsequent 
surface plasmon resonance (SPR) experiments 
revealed, both the fast association (ka = 2.1 × 106 M-1 s-1 
for human CatB, ka = 7.5 × 105 M-1 s-1 for mouse CatB) 
and very slow dissociation (kd = 6.7 × 10-5 s-1 for 
human CatB, kd = 1.5×10-4 s-1 for mouse CatB) of 
DARPin 8h6 contributed to the high affinity (Fig. S5, 
Table 1). The interaction with the zymogen form of 
CatB, proCatB, was substantially weaker (KD = 7.1 
nM) due to the much slower association of the 
complex (ka = 1.4 × 104 M-1 s-1), whereas the 
dissociation was not affected significantly (kd = 1.0 × 
10-4 s-1) (Fig. S6a, Table 1). 
 
Table 1. Binding characterization of DARPin 8h6 to human and 
mouse CatB as determined by enzyme inhibition (Fig. 1c and Fig. 
S4) and surface plasmon resonance (Figs. S5, 6).  
 Inhibition SPR 
Ki [pM] α β ka [M-1 s-1] kd [s-1] KD [nM] χ2 [%Rmax] 
Human CatB 34 ± 1 6.6 0.15 2.1 × 106 6.6 × 10-5 0.031 2.2 % 
Mouse CatB 35 ± 3 6.1 0.064 7.5 × 105 1.5 × 10-4 0.20 12.5 % 
Human proCatB    1.4 × 104 1.0 × 10-4 7.1 3.6 % 
 
 
In the selection process, another CatB-inhibitory 
DARPin, DARPin 81, was also obtained and 
characterized (Fig. S7b, c). DARPin 81 shared 15 of the 
27 variable site residues with DARPin 8h6 and had 
90.1 % overall sequence identity (Fig. S1a). Although 
DARPin 81 had an analogous inhibitory profile with 
DARPin 8h6, it was found to have a substantially 
lower affinity for CatB in the low nanomolar range 
(Ki= 4.1 nM; Fig. S4f-i). However, this was still a 
sufficiently high affinity to enable the use of DARPin 
81 in some of the experiments as a competitive binder 
of DARPin 8h6 for CatB. Non-selective DARPin E3_5 
[46] did not bind to CatB, nor did it have any effect on 
CatB activity, and was used as a control DARPin 
throughout the experiments (Fig. S7a, c). 
Extensive interactions with the CatB left 
domain account for the tight binding of 
DARPin 8h6 
To understand the interactions between CatB 
and DARPins 8h6 and 81, crystal structures of the 
complexes were determined at 2.76 Å and 1.81 Å 
resolutions, respectively. The DARPin 8h6 complex 
crystallized with two pairs of molecules in the 
asymmetric unit, whereas DARPin 81 crystallized 
with one. The high-quality diffraction data enabled us 
to unambiguously build models of DARPin 81 and 
CatB apart from their termini. By contrast, the lower 
resolution crystals yielded a weaker diffraction of the 
DARPin 8h6 complex, which enabled us to build the 
structures along the whole chain length. However, the 
refinement and density maps in part pulled the local 
geometry out of the minima that would correspond to 
a model that scored well according to the validation 
criteria (Table S1).  
The CatB structures of the two DARPin 8h6 
complexes from the asymmetric unit superimpose 
onto the CatB structure from the DARPin 81 complex 
with a RMSD over all of the CA atoms of 0.55 Å and 
0.62 Å, respectively, whereas among them the RMSD 
is 0.61 Å. The relative positions of both DARPin 8h6 
structures are shifted > 3 Å away from the DARPin 81 
structure using the CatB superimposition parameters, 
whereas the superimposition of the DARPins over 161 
residues yielded a RMSD of 1.7 Å and 1.8 Å, 
respectively. While the structures indicate the same 
binding mode, the rather large shift of 3 Å indicates 
considerable differences among the binding contacts.  
The concave binding surface of both DARPins 
includes the variable site residues on the β-turns of 
the internal repeats and C-cap; this surface forms the 
majority of interactions with CatB on the enzyme’s 
interdomain interface as well as the surface of the 
L-domain, leaving the active site Cys-His dyad 
exposed to solvent (Fig. 2a). The central interactions of 
both DARPins are formed with the CatB S65 - A77 
loop that builds the left side of the surface of the S2 
and S3 substrate-binding sites (Fig. 2b). Intriguingly, 
both DARPins share the variable site residues Y46, 
R48, W78, Y80, E89 and R111, which contribute to 
interactions with CatB in this area of low structural 
conservation in the cathepsin family (Fig. S8), 
providing an explanation for the specificity. However, 
DARPin 8h6 forms additional contacts in this area 
through W122 and interacts with R85-K86 at the end 
of the third CatB alpha helix on the L-domain through 
W56 (Fig. 2c), whereas DARPin 81 has S122 and N56 
at these positions, which do not substantially 
contribute to binding. The consequence is a slight shift 
of DARPin 8h6 towards the CatB L-domain compared 
to DARPin 81, as well as a substantial increase in the 
interaction surface. The average interface area of the 
DARPin 8h6-CatB complexes is 973 Å2 compared to 
860 Å2 for the DARPin 81-CatB complex (as calculated 
by the PDBePISA server, http://www.ebi.ac.uk/ 
pdbe/pisa/), which correlates well with the 
significantly higher affinity of DARPin 8h6. Both 
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interaction surfaces and affinities are consistent with 
the previously reported DARPin-target protein 
complex [35]. 
Next, we compared the crystal structures of the 
DARPin 8h6-CatB complex with the crystal structure 
of proCatB [47]. Superimposition of the structures 
showed no considerable differences in the CatB 
structure apart from the occluding loop region, which 
is displaced in proCatB. The partial steric overlap 
between DARPin 8h6 and the N-terminal propeptide 
in proCatB, which occupies the entire active site cleft, 
suggests that the much higher affinity of CatB for 
DARPin 8h6 than for the propeptide (35 pM vs. ~1 
nM; ref [48]) could lead to the displacement of the 
propeptide by the DARPin (Fig. 2d). This is consistent 
with the substantially lower affinity of DARPin 8h6 
for proCatB than for the mature CatB (Table 1). The 
formation of the complex between DARPin 8h6 and 
proCatB was confirmed by size-exclusion 
chromatography and by streptavidin pull-down with 
a biotinylated DARPin 8h6, using a cell extract from 
the human monocytic cell line THP-1 (Fig. S6b, c), 
although the difference in the rates of association and 
affinities results in a clear preference for binding of 
DARPin 8h6 to the mature form of the enzyme. 
DARPin 8h6 selectively interacts with 
membrane-associated and secreted cathepsin 
B, and inhibits cancer cell invasion 
Having shown selective binding of DARPin 8h6 
to CatB in vitro, we next tested whether it can also 
bind to CatB translocated to the membrane or secreted 
into the extracellular space by tumour and other cells 
including macrophages. As models we selected 
human glioblastoma cell line U-87 MG and human 
cervical adenocarcinoma cell line HeLa, primary 
mouse PyMT cells and bone marrow-derived 
macrophages (dBMM), and mouse 4T1 cells. The 
mouse cells were selected because of the PyMT and 
4T1 mouse breast cancer models used in further 
studies, and in which CatB is known to have a role in 
tumour development by contributing to pericellular 
proteolysis in both tumour and stromal cells, 
particularly macrophages [49, 50]. The main reason to 
select the two human cell lines was their dramatically 
different expression of CatB 
(http://www.proteinatlas.org/ENSG00000164733-CT
SB/cell), which makes them suitable for evaluating 
the selectivity of DARPin 8h6.  
In both PyMT primary cells and 4T1 cultures, 
CatB was found to be abundantly secreted to the 
extracellular space in the zymogen form. By contrast, 
the enzyme was secreted as both the zymogen and 
mature enzyme from the primary dBMM, which were 
found to express considerably more CatB than 
tumour cells (Fig. 3a). In U-87 MG human cells the 
secreted CatB was found to be a mixture of the mature 
(single chain (scCatB) and heavy chain (hcCatB)) and 
the zymogen form (proCatB), whereas in cell extracts 
the majority of CatB was in the mature single chain 
form. By contrast, no secreted CatB was observed in 
HeLa cells, and only a very low amount of primarily 
mature CatB was observed in cell extracts (Fig. 3a). 
Next, we evaluated the levels and activity of 
pericellular CatB in different cells. Higher levels of 
membrane-associated CatB in dBMMs compared to 
tumour cells were confirmed by detecting CatB in live 
cells with CatB-specific antibodies (Fig. 3b). 
Consistent with this, a significantly higher pericellular 
CatB activity was detected in dBMMs compared to the 
tumour cells (Fig. 3c). Significant amounts of 
membrane-associated CatB and pericellular CatB 
activity were also observed in U-87 MG cells. 
However, no CatB was detected in HeLa cells, 
consistent with very low levels of the enzyme in these 
cells (Fig.3b, c).  
 
 
Figure 2. Structure of human CatB in complex with DARPin 8h6. (a) Superimposition of complexes between CatB (grey) and DARPins 8h6 (red) and 81 
(blue). (b) Close-up of the binding interface (top view) and (c) (side-view). The CatB active site, S65-A77 loop and R85-K86 residues are in yellow, light-green and 
dark-green, respectively. DARPin 8h6 (left) is shown in red and DARPin 81 (right) in blue. Variable site DARPin residues are shown as sticks. (d) Superimposition of 
DARPin 8h6-CatB complex with the crystal structure of proCatB (PDB ID 3PBH). In all figures, superimposition was performed using CatB residues 1-254 (mature 
enzyme numbering). All figures were prepared in PyMOL. 
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Figure 3. DARPin 8h6 interacts with membrane-associated and secreted CatB in mouse cells. (a) Western-blot detection of the active CatB and zymogen 
(proCatB) protein levels in whole cell extracts (CE) and conditioned media (CM) of tumour cells (PyMT, 4T1, U-87 MG, HeLa) as well as differentiated bone-marrow derived 
macrophages (dBMM). Actin was used as a loading control. (b) Immunodetection of cell membrane-associated CatB. An equal numbers of cells were grown on a 96-well plate. 
Active endocytosis was blocked by cooling cells to 4 °C for 1 hour, followed by immunodetection with antibodies against mouse CatB for PyMT, 4T1 cells and dBMMs or against 
human CatB for U-87 MG and HeLa (1 h incubation) and Alexa488-conjugated secondary antibodies (1 h incubation). Cell-associated fluorescence after washing was measured 
by a plate reader (Tecan Infinite) with ex/em = 488/520 nm at nine separate locations in each well. Background fluorescence from secondary antibodies was subtracted from the 
measurements. The experiment was performed in triplicate and is presented as the mean ± standard error of the relative fluorescence intensity. (c) Cell membrane-associated 
CatB activity. Equals number of cells on a 96-well plate were assayed with 50 µM z-Arg-Arg-AMC for CatB activity as described in the Materials and methods. CatB activities are 
presented as the mean ± standard error of relative fluorescence units per second. (d) Detection of CatB by DARPin 8h6 on the cell membrane of cells. The experiment was 
performed as in b with biotinylated DARPin 8h6 (100 nM) or nonselective DARPin E3_5 (100 nM) and Streptavidin-Alexa488 used instead of antibodies. Unlabelled competitor 
DARPins (1 µM) were preincubated with cells for 30 min where indicated. (e) DARPin 8h6 inhibition of cell membrane-associated CatB activity. The experiment was performed 
as in c, with the addition of a preincubation step for cells with 100 nM DARPins. (f) Cell invasion of U-87 MG spheroids in the presence of 5 µM CA074 (or DMSO control) or 
1 µM DARPins. Quantification of spheroid volumes after 24 h of invasion and representative images of spheroids are shown. Scale bar = 200 µm. * p < 0.05 ** p < 0.01 *** p < 
0.0001 
 
We next evaluated whether DARPin 8h6 can 
interact with membrane-associated CatB. Since 
DARPins are known to be endocytosed [51], 
endocytosis was blocked prior to the experiment. We 
used a biotinylated form of DARPin 8h6 and indeed 
detected the membrane-associated CatB in the U-87 
MG cells, while there was no binding to the 
CatB-negative HeLa cells (Fig. 3d), confirming 
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selectivity of this DARPin. In the control experiment, 
only minimal unspecific binding by the nonselective 
control DARPin E3_5 was observed. The selective 
nature of binding to CatB was confirmed in a 
competition experiment in which cells were 
preincubated with unlabelled DARPin 8h6 or the 
competitor DARPin 81. In both cases, preincubation 
significantly reduced the binding of the labelled 
DARPin 8h6, pointing to a selective interaction of 
DARPin 8h6 with membrane-associated CatB (Fig. 
3d). As shown in Fig. 3d, a significantly higher 
association of the biotinylated DARPin 8h6 to dBMMs 
was detected compared to PyMT tumour cells, 
reflecting the differences in the CatB expression 
patterns and membrane association in these two cell 
types. As with the U-87 MG cells, preincubation with 
unlabelled DARPin 8h6 or competitor DARPin 81 
reduced the signal in dBMMs and PyMT cells as well. 
Due to the inhibitory nature of DARPin 8h6, we 
also evaluated the potential to block pericellular CatB 
activity. This activity was completely inhibited by 
DARPin 8h6 already at 100 nM in U-87 MG, dBMM, 
PyMT and 4T1 cells, while the nonselective control 
DARPin E3_5 had no significant effect on CatB 
activity under the same conditions (Fig. 3e). Since 
proteolysis by CatB contributes to cancer cell 
invasion, we tested how DARPin 8h6 affects invasion 
of U-87 MG cell spheroids through Matrigel. DARPin 
8h6 substantially inhibited invasion, comparably to 
the irreversible covalent CatB inhibitor CA074, while 
the nonselective DARPin E3_5 had no significant 
effect (Fig. 3f). 
DARPin 8h6 binds to CatB in the tumour 
microenvironment 
Next, the interaction of DARPin 8h6 with CatB 
was tested in the PyMT tumour microenvironment. 
We performed a two-step histochemical test on native 
tumour tissues that consisted of (i) an evaluation of 
DARPin binding to CatB and (ii) in situ zymography 
using a CatB-selective substrate z-Arg-Arg-4MβNA in 
tissue slices (Fig. 4a). Biotinylated DARPin 8h6 bound 
to CatB in the tissue slices, while the nonselective 
control DARPin E3_5 did not (Fig. 4b). However, no 
binding was observed in fixed histological samples, 
most likely due to the destruction of the extended 
three-dimensional epitope on CatB during the fixation 
procedure (data not shown). In addition, inhibition of 
CatB enzymatic activity by DARPin 8h6 was 
observed, whereas DARPin E3_5 did not have an 
effect. DARPin 8h6 exhibited a similar inhibitory 
efficacy as CA074 (Fig. 4c). 
In vivo tumour imaging with fluorescently 
labelled DARPin 8h6 
In the final set of experiments, we evaluated the 
in vivo imaging potential of DARPin 8h6 in mice. Since 
in vivo imaging requires appropriately labelled 
DARPins, we next evaluated whether 
Cy5.5-fluorescently labelled DARPin 8h6, conjugated 
at the same site on the C terminus as the biotin tag, 
could also bind CatB in cells. Indeed, Cy5.5-labelled 
DARPin 8h6 interacted with CatB at the cell 
membrane after blocking endocytosis, while the 
nonselective DARPin E3_5 did not (Fig. S9). 
 
 
Figure 4. DARPin 8h6 selectively interacts with CatB in PyMT 
tumour tissues. (a) Schematic representation of the in situ imaging of CatB 
localization and activity in native cryopreserved tumour tissue. (b) C-terminally 
biotinylated nonselective DARPin E3_5 (1 µM) or CatB-selective DARPin 8h6 
(1 µM) were incubated for 30 min with native PyMT tumour tissue slices, 
followed by detection by streptavidin-A488 (green). Cell nuclei were stained by 
DAPI (blue). (c) Native PyMT tumour tissue slices were incubated for 1 h with 
the fluorogenic CatB-selective substrate z-Arg-Arg-4MβNA (green) and 
DARPins E3_5 (1 µM) or 8h6 (1 µM), or the irreversible covalent inhibitor 
CA074 (1 µM). Cell nuclei were stained with DAPI (blue; scale bar, 50 µm). 
 
Since DARPin 8h6 binding to serum proteins 
could significanlty influence the biodistribution 
profile of the DARPin in vivo, we next incubated 
biotinylated DARPin 8h6 for 24 h at 37 °C in human 
serum, separated the mixture on a size-exclusion 
column and analysed the collected fractions. 
Western-blotting analysis revealed that the DARPin 
remained a monomeric protein and was eluted in the 
same fractions as purified DARPin in buffer (Fig. S10), 
supporting its in vivo use. In the next step we 
examined the pharmacokinetic profile of 
Cy5.5-labelled DARPins 8h6 and E3_5 in healthy mice. 
Both DARPins had fast biphasic blood clearance with 
the fast half-life below 2 min and the slow half-life of 
78 min (DARPin E3_5) and 48 min (DARPin 8h6), 
respectively. More than 90 % of DARPin 8h6 was 
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cleared from blood in the first two hours and less than 
0.5 % was retained after 24 h (Fig. S11).  
Finally, we evaluated whether the DARPin 8h6 
interaction with CatB could be monitored in vivo in 
tumour-bearing mice. We administered 
Cy5.5-labelled DARPin 8h6 i.v. and followed its 
biodistribution using non-invasive whole-body 
imaging and ex vivo imaging of isolated organs. 
Initially we evaluated DARPin 8h6 in the orthotopic 
PyMT tumour model. In this model, DARPin 8h6 had 
already rapidly localized to tumours 30 min post 
administration and was selectively retained at the 
tumour site for up to 72 h post administration (Fig. 5b, 
c, Fig. S12). By contrast, the nonselective control 
DARPin E3_5 only displayed a very minor elevated 
fluorescence signal in tumours at early time-points 
and was not retained after the 3 h time point, likely 
due to the enhanced permeability and retention (EPR) 
effect in the leaky tumour vasculature. Moreover, 
when the ratios of the fluorescence signals between 
the tumour and contralateral mammary gland in 
individual mice were examined, DARPin 8h6 showed 
significantly elevated ratios at all time-points 
compared to DARPin E3_5, with a peak at 3 h post 
administration (Fig. 5d). The selective nature of 
DARPin 8h6 was further evaluated by an in vivo 
competition assay, where an excess of unlabelled 
DARPin 8h6 was administered to tumour-bearing 
mice 1 h before the administration of Cy5.5-labelled 
DARPin 8h6. This resulted in a significant reduction 
of the tumour signal as well as the ratios of the 
fluorescent signals between the tumours and 
contralateral mammary glands 3 h after 
administration (Fig. S13b, c, d). The lower-affinity 
DARPin 81 was also selectively retained in tumours 
after i.v. administration, although the tumour signals 
were significantly lower than with DARPin 8h6 (Fig. 
S14), likely due to the lower affinity of this DARPin 
for CatB. 
Next, we examined the DARPin distribution in 
isolated organs 3 h and 72 h post i.v. administration. 
The fluorescence signal from DARPin 8h6 was 
significantly higher in tumours than in other organs at 
both time-points, except for the liver and kidneys, 
which are involved in DARPin secretion from the 
body (Fig. 5e-h). Notably, there was specific 
up-regulation of DARPin 8h6 in comparison with the 
nonselective DARPin E3_5 in the tumour, as well as in 
the liver and spleen, in agreement with the high CatB 
content in these tissues [52]. Mice that were 
pre-treated with unlabelled DARPin 8h6 had 
significantly reduced tumour and liver signals after 
Cy5.5-labelled DARPin 8h6 administration, pointing 
to selective binding of DARPin 8h6 to CatB in these 
tissues (Fig. S13e, f). Considerable amounts of 
DARPin 8h6 were detected in tumours even after 72 h 
(1.5 % ± 0.3 % of the injected dose, compared to 5.4 % 
± 0.7 % at 3 h, as determined from the fluorescence 
ratio of the tumour tissue and the injected DARPin 
8h6-Cy5.5 solution (average radiant fluorescence = 8.3 
× 109 (p/s/cm²/sr) / (µW/cm²))), indicative of 
substantial DARPin uptake by cells in the tumour 
microenvironment. This was additionally confirmed 
by immunohistochemical analysis of tumours 
following DARPin 8h6 administration, which showed 
that DARPin co-localized with CatB (Fig. S15) and 
was taken up by both tumour cells and F4/80-positive 
tumour-associated macrophages (Fig. 5i). To further 
validate the interaction between DARPin 8h6 and 
CatB in the tumour microenvironment, we performed 
streptavidin pull-down assay of tumour tissue after 
intratumoural application of biotinylated DARPin 8h6 
(Fig. 5j). The DARPin interacted only with the mature 
form of CatB and not with the zymogen, which is in 
agreement with the significantly higher affinity of the 
DARPin for this form of CatB. DARPin 81 also bound 
only mature CatB, while there was no interaction with 
the nonselective control DARPin E3_5.  
To investigate whether DARPin 8h6 can 
generally be used for imaging secreted CatB in the 
tumour microenvironment, we applied the 4T1 
model, which is a highly aggressive model of breast 
cancer. Again, DARPin 8h6 selectively localized to the 
mammary gland tumours, as confirmed by both in 
vivo whole-body imaging and ex vivo imaging of 
isolated organs 3 h after administration. In 
comparison with the nonselective control DARPin 
E3_5, DARPin 8h6 displayed higher accumulation at 
the tumour site (Fig. 6a, b) as well as a significantly 
higher ratio of tumour-to-contralateral mammary 
gland (Fig. 6c). Ex vivo analysis confirmed that there 
were elevated levels of fluorescence in tumours, as 
well as liver and spleen, from mice administered 
DARPin 8h6 compared to DARPin E3_5 (Fig. 6d, e, 
Fig. S15), consistent with high CatB levels in these 
tissues. As in the PyMT model, the DARPin 8h6 
signals in tumours were significantly higher 
compared to other organs, except for the liver and 
kidneys, which are involved in DARPin secretion. 
This evidence supports the broad usefulness of 
DARPin 8h6 in in vivo diagnostic imaging of CatB.  
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Figure 5. Non-invasive optical tumour imaging by fluorescently labelled DARPin 8h6 in PyMT tumour model. (a) Schematic representation of the 
imaging experiment outline with the orthotopic PyMT tumour model. (b) PyMT cells were injected into the left inguinal fat pads of FVB/N mice and allowed to grow 
until 100-150 mm3. C-terminally Cy5.5-labelled DARPin 8h6 or nonselective DARPin E3_5 was injected i.v. (1 nmol in 100 µL) and epi-fluorescent images were taken 
at designated time-points after administration. False blue-hot colouring of the radiant efficiency (radiance (photons per second per square centimetre per steradian) 
per incident excitation power (microwatt per square cm)) is overlaid on bright-field images. (c) Quantification of the average radiant efficiency from b in tumours and 
contralateral mammary glands as the means ± standard error. Regions of interest (ROI): tumour – red circle, contralateral mammary gland – black circle. (d) 
Tumour-to-contralateral mammary gland ratios of the average radiant efficiency in individual mice from b represented as the means ± standard error. *** p<0.001, 
** p<0.01 (e, f) DARPin distribution in isolated organs 3 h and (g, h) 72 h after administration. False blue-hot images of the radiance efficiency are overlaid on 
bright-field images. Representative images of four mice per group are shown. The average radiant efficiency from isolated organs is quantified as the mean ± standard 
error. Li = liver, S = spleen, Ln = lymph nodes, T = tumour, H = heart, Lu = lungs, K = kidneys. *** p<0.001, ** p<0.01, * p<0.05 (i) Immunohistochemical analysis of 
cryopreserved tumours 3 h after i.v. administration of Cy5.5-labelled DARPin 8h6 (red). The tissue sections were stained with macrophage marker F4/80 (green) and 
for cell nuclei (DAPI, blue). Scale bar, 20 µm; inlet scale bar, 10 µm. (j) DARPin pull-down of CatB from tumour tissue 30 minutes after intratumoural administration 
of 5 nmol of C-terminally biotinylated DARPins. The streptavidin-bound fraction was separated using SDS-PAGE and immunoblotted against CatB. The presence of 
DARPins was confirmed by detection with streptavidin-HRP. Total extract from tumour (50 µg) was added to visualize different forms of CatB in the tumours. 
proCatB = procathepsin B, scCatB = single chain CatB, hcCatB = heavy chain CatB. 
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Figure 6. Non-invasive optical tumour imaging by fluorescently labelled DARPin 8h6 in 4T1 mouse tumour model. (a) 4T1 cells were injected into the left inguinal fat pads of 
Balb/c mice and allowed to grow until 100-150mm3. C-terminally Cy5.5-labelled DARPin 8h6 or nonselective DARPin E3_5 was injected i.v. (1 nmol in 100 µL), and epi-fluorescent images were 
taken 3 h after administration. False blue-hot colouring of the radiant efficiency (radiance (photons per second per square centimetre per steradian) per incident excitation power (microwatt 
per square cm)) is overlaid on bright-field images. (b) Quantification of the average radiant efficiency from a in tumours and contralateral mammary glands is shown as the means ± standard 
error. Regions of interest (ROI): tumour – red circle, contralateral mammary gland – black circle (c) Tumour-to-contralateral mammary gland ratios of the average radiant efficiency in 
individual mice from a represented as the means ± standard error. * p<0.05 (d, e) DARPin distribution in isolated organs 3 h after administration. False blue-hot images of the radiance 
efficiency are overlaid on bright-field images. Representative images of four mice per group are shown. The average radiant efficiency from each organ is quantified below as the mean ± 
standard error. Li = liver, S = spleen, Ln = lymph nodes, T = tumour, H = heart, Lu = lungs, K = kidneys *** p<0.001, * p<0.05. 
 
Discussion 
Non-invasive imaging of tumour-associated 
proteases has been widely investigated in the past, 
primarily because several proteases exhibit 
up-regulated expression and activity in tumour 
tissues and can therefore potentially be used in cancer 
diagnostics. Among these tumour-associated 
proteases, cysteine cathepsins have been particularly 
well investigated, with numerous fluorescent ABPs 
and substrates reported that showed good selectivity 
for target proteases and enabled in vivo detection of 
tumours in several mouse models as well as ex vivo 
detection in human biopsy samples [21, 53]. One 
important enzyme is CatB (Fig. 7a), which has already 
been proposed as a diagnostic target in preclinical 
tumour imaging, particularly by employing quenched 
NIR fluorescent substrates [54, 55] and a 
nanoparticulate CatB-targeting system [12]. To 
overcome the low penetration of fluorescence light 
and therefore its very limited use in human 
non-invasive diagnostics, we applied a new concept 
for highly selective targeting of CatB that could be 
applied to other proteases using the small and rigid 
non-immunoglobulin DARPin scaffold to obtain 
highly selective binders. The main advantage of this 
approach is that DARPins can be modified by various 
imaging tags without affecting their binding 
properties, including fluorescent and PET/SPECT 
tracers [33, 56] as well as other functional tags such as 
polymers or serum albumin to modify 
pharmacokinetics [31, 32]. A further advantage is that 
the interaction site is not limited to the active site cleft, 
as in ABPs and substrates (Fig. 7b). Although this 
approach has found substantial use in developing 
extremely selective binders to various receptors, 
including for potential therapeutic applications [57, 
58], it has not been used in cellular or non-invasive 
diagnostic imaging of proteases. Moreover, the only 
protease-targeting DARPins were developed as 
selective inhibitors of a tobacco virus protease [59] or 
caspases [35, 60] to help elucidate the molecular basis 
of their specificity.  
Using this approach, we developed a subset of 
DARPins that bound to both human and mouse CatB. 
This is of particular importance, as it allows 
immediate transfer of DARPins from mouse to human 
systems without affecting their binding properties 
and selectivity. We further characterized DARPins 
8h6 and 81, with a major focus on DARPin 8h6. This 
DARPin selectively binds and inhibits only human 
and mouse CatB with very high affinity in the 
picomolar range (Ki ~ 35 pM), but not the structurally 
related cathepsins L, K, S or X. This is a substantially 
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higher affinity than the affinity of cystatin C (Ki ~ 150 
pM; ref [61]), which is the best endogenous inhibitor 
of CatB. Both the specificity and high affinity can be 
explained on a structural basis, since the DARPin 
binds to an extended region on the left CatB domain, 
which is poorly conserved in the family of cathepsins, 
as well as to a part of the active site cleft S2 and S3 
subsites, but does not clash with the occluding loop 
residues, thereby differing from cystatins [62]. By 
contrast, DARPin 81, which binds to essentially the 
same region on CatB and was also specific for CatB, 
exhibited affinity that was lower by two orders of 
magnitude (Ki ~ 4.1 nM) due to the absence of two 
important tryptophan residues in the sequence. 
Extremely high affinity is vital for successful in vivo 
targeting, as demonstrated previously using 
differently modified HER2-targeting monovalent 
DARPins as a model. In that study, the high-affinity 
DARPin G3 (Kd ~90 pM) led to significantly higher 
tumour targeting and accumulation than low-affinity 
mutant DARPins (Kd >1 nM), which lack critical 
interface residues that are involved in binding [33]. In 
agreement with this, the high affinity-binding 
DARPin 8h6 exhibited substantially higher tumour 
accumulation than the low-affinity DARPin 81 in the 
PyMT mammary gland mouse model (Fig. 5, S14). 
Substantial accumulation of DARPin 8h6 in the 
tumour was observed after only 30 min, with a peak 
value of the signal ratio between the tumour and 
contralateral mammary gland after 3 h, which is 
comparable to quenched ABPs [19]. The signal ratio 
between the tumour and contralateral mammary 
gland for DARPin 8h6 remained very high even at 24 
h, 48 h and 72 h time points, indicating that reliable in 
vivo imaging of tumours can be achieved for a very 
long time after initial low unspecific background 
signal is washed away. Moreover, the 
pharmacokinetic behaviour and unspecific 
background signals generated by the DARPin might 
be further improved by using alternative imaging 
reporters (i.e., different fluorophores, PET or SPECT 
reporters) or replacing the N-terminal His-tag with 
His-Glu-tag [56]. 
Moreover, our study also confirmed the presence 
of high levels of CatB in the tumour 
microenvironment. Although this tumour CatB, 
which predominantly originated in macrophages, was 
secreted as both the zymogen and mature form from 
dBMM in the culture (Fig. 3a), DARPin 8h6 only 
labelled the mature form in the tumour and not the 
zymogen (Fig. 5j), consistent with the preferential 
binding of the DARPin to this CatB form due to a 
steric clash with the propeptide that results in a 
diminished rate of association and affinity for the 
zymogen. This is in agreement with the recent results 
of a proteomic analysis of PyMT tumour interstitial 
fluids, which showed that at least part of the secreted 
CatB exists in the zymogen proCatB form [63]. Our 
results therefore support previous findings, where a 
significant proportion of the secreted zymogen has 
been found to be activated in the acidic extracellular 
milieu in tumours [64, 65]. Importantly, the DARPin 
signal in the tumour was clearly detectable at least 
until 72 hours post-administration (Fig. S12), which 
provides an excellent opportunity for theranostic 
applications based on CatB targeting. The DARPin 
can also be used as the targeting moiety in an 
antibody-drug conjugate (ADC)-like approach, 
especially since conjugation is achieved via the 
C-terminus and thereby does not affect the interaction 
with the target. However, DARPin 8h6 is not really 
suitable for imaging liver tumours. DARPin 8h6 
namely partially accumulated in the liver as a 
consequence of binding to CatB (Fig. S13), which is 
highly abundant in this organ [52]. Nevertheless, 
masking the binding region with polymers such as 
PEG might reduce the CatB-specific liver signal. 
Moreover, conjugating the polymer to the DARPin via 
a linker that is cleavable by another tumour-specific 
protease, might result in selective tumour targeting 
even in the liver and improve the overall imaging 
quality as has been recently suggested [66]. 
 
 
Figure 7 | Unconventional targeting of an emerging tumour target. (a) Schematic 
illustration of dysregulated CatB secretion from cancer and stromal cells (i.e., 
tumour-associated macrophages, TAMs) in the tumour microenvironment. In healthy 
tissues, CatB is contained intracellularly in endo-lysosomal vesicles. (b) Structural 
conservation (determined by ConSurf (http://consurf.tau.ac.il/)) within the cathepsin family 
in human CatB. Cathepsins have highly conserved active site clefts, making truly selective 
targeting using activity-based approaches difficult, whereas other regions with high 
structural variability provide uncharted territory for probe design with affinity probes such 
as DARPin 8h6. Engineering a unique cysteine residue at the C terminus of DARPins enables 
site-specific labelling with various chemical tags for the purpose of imaging, pull-down or 
drug delivery. The image was produced in PyMOL (www.pymol.org). 
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DARPin 8h6 is not just an excellent diagnostic 
agent for non-invasive cancer imaging based on CatB 
but is also an excellent tool for studying CatB function 
in cells. A significant amount of pericellular and 
membrane-attached CatB was detected in dBMM, 
consistent with previous findings [9, 10, 12]. 
Moreover, using the DARPin 8h6 inhibitory potential 
we successfully reduced tumour cell invasion, where 
pericellular proteolysis of extracellular matrix by CatB 
importantly contributes to cancer spreading [43]. 
Furthermore, DARPin 8h6 is the best macromolecular 
inhibitor of CatB found to date, thereby offering 
numerous additional possibilities, ranging from 
selective inhibition of CatB in cellular studies to 
identification of the physiological ligands of CatB 
using affinity pull-down as well as subsequent 
identification of the ligands via mass spectrometry. In 
addition, selective inhibition of individual 
intracellular cathepsins, including CatB, is very 
difficult to achieve using small molecule inhibitors 
due to their limited selectivity, including the most 
widely used CatB cell-permeable inhibitor 
CA074-OMe [67]. Therefore, transgenic expression of 
DARPin 8h6 in mammalian cells could serve as a 
powerful tool in biomedical research.  
Conclusions 
In summary, the use of engineered 
macromolecules, such as DARPins, in non-invasive 
diagnostic imaging is a new approach in targeting 
tumour-associated proteases that is completely 
different from the standard small molecule-based 
approaches. The strategy is applicable to secreted or 
membrane-associated proteases, particularly where 
complete selectivity in the active site is difficult to 
achieve. In addition, such highly selective DARPins 
provide a major opportunity for in vivo validation of 
the therapeutic compounds targeting these proteases. 
Moreover, the DARPins can be used both as inhibitors 
and imaging agents, thereby combining the properties 
of small molecule inhibitors and ABPs for various 
theranostic applications.  
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